Alternate site health provider Option Care Health (NASDAQ: OPCH) fell short of the market’s revenue expectations in Q1 CY2026 as sales only rose 1.3% year on year to $1.35 billion. The company’s full-year revenue guidance of $5.73 billion at the midpoint came in 3.5% below analysts’ estimates. Its non-GAAP profit of $0.40 per share was 8.1% above analysts’ consensus estimates.
Is now the time to buy OPCH? Find out in our full research report (it’s free for active Edge members).
Option Care Health (OPCH) Q1 CY2026 Highlights:
- Revenue: $1.35 billion vs analyst estimates of $1.40 billion (1.3% year-on-year growth, 3.3% miss)
- Adjusted EPS: $0.40 vs analyst estimates of $0.37 (8.1% beat)
- Adjusted EBITDA: $104.8 million vs analyst estimates of $103 million (7.8% margin, 1.7% beat)
- The company dropped its revenue guidance for the full year to $5.73 billion at the midpoint from $5.9 billion, a 3% decrease
- Management reiterated its full-year Adjusted EPS guidance of $1.87 at the midpoint
- EBITDA guidance for the full year is $492.5 million at the midpoint, in line with analyst expectations
- Operating Margin: 5.4%, in line with the same quarter last year
- Market Capitalization: $3.19 billion
StockStory’s Take
Option Care Health reported a mixed first quarter, with management citing operational headwinds in its chronic therapy segment and a challenging reset in patient census resulting from benefit reverification and changes in insurance plan designs. CEO John Rademacher characterized the quarter as “mixed,” noting that while acute therapy performance was strong, revenue growth fell below expectations due to a higher volume of patient reauthorizations and unfavorable shifts in therapy mix. Management acknowledged that these dynamics led to an “unfavorable drop in census” and stated that the process of rebuilding would take time, reflecting a cautious outlook after the quarter’s underperformance.
Looking forward, Option Care Health’s updated guidance is shaped by the need to rebuild chronic therapy patient volumes and adapt to changes in benefit design and formulary management across health plans. Management is prioritizing enhanced commercial execution, investments in operational capacity, and targeted cost controls to balance growth with profitability. CFO Meenal Sethna emphasized, “We are continuing to invest in our commercial resources and will make further adjustments to our cost structure if needed,” while Rademacher reiterated that the foundation remains strong but that a successful year will depend on executing these strategic initiatives and stabilizing patient census.
Key Insights from Management’s Remarks
Management attributed the quarter’s underperformance to disruptions in the chronic therapy segment, specifically related to patient census resets and benefit reverification delays, while highlighting continued strength in acute therapies and ongoing investments in commercial infrastructure.
-
Chronic therapy headwinds: The company experienced a higher-than-expected loss of chronic therapy patients, particularly in its chronic inflammatory disease (CID) portfolio, due to benefit reverification and insurance plan changes. This resulted in a reset of patient census and a less favorable mix, directly impacting gross profit and requiring updated assumptions for the year.
-
Acute therapy outperformance: Acute therapy revenue grew at a high single-digit rate, outpacing market growth. Management credited investments in referral relationships, clinical value realization, and local execution for this strong performance. Acute therapies carry higher gross margins, helping partially offset chronic segment pressures.
-
Benefit reverification complexity: The first quarter saw a doubling of patients affected by insurance benefit design changes, leading to elongated approval cycles and delayed patient onboarding. Management described this as a “bolus of activity” that created operational bottlenecks and increased administrative workload across teams.
-
Strategic commercial investments: To recover lost census and accelerate growth, Option Care Health is increasing the size and capability of its commercial team, rebalancing coverage across priority accounts, and leveraging technology to improve referral conversion and workflow efficiency. These actions are intended to drive both short-term recovery and long-term growth.
-
Alliances and payer partnerships: Management emphasized positive developments with health plans and site-of-care initiatives, noting that existing programs are delivering cost savings for payers and growing patient satisfaction. Pharma partnerships remain active, with ongoing development for new therapy launches and expanded engagement in complex drug delivery.
Drivers of Future Performance
Management expects a challenging environment in the near term, with future performance driven by rebuilding chronic therapy census, operational execution, and maintaining momentum in acute therapies.
-
Chronic portfolio rebuild: The company’s outlook depends on recovering patient volumes lost in the CID segment, which management believes will take several quarters. The pace of recovery will hinge on the effectiveness of commercial investments and success in converting referrals into active patients.
-
Acute and specialty growth: Acute segment growth is expected to continue above market rates, supported by strengthened local partnerships and expanded clinic capabilities. Management is also targeting growth in specialty areas such as immunoglobulin neuro therapies and oncology infusion, which are viewed as opportunities to diversify revenue streams.
-
Cost management and efficiency: Option Care Health is implementing tighter cost controls and variable expense reductions, including adjustments to incentive compensation and SG&A. These measures are intended to support profitability while investments in commercial and operational infrastructure are deployed to drive growth.
Catalysts in Upcoming Quarters
In the quarters ahead, the StockStory team will be watching (1) the pace of patient census recovery in chronic therapies, (2) sustained outperformance and margin contribution from acute therapy services, and (3) the effectiveness of commercial and operational investments in driving new patient referrals and conversions. Progress in payer and pharma partnerships, as well as execution on specialty product launches, will be additional indicators of momentum.
Option Care Health currently trades at $20.24, down from $26.87 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
